Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAYTULLA vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 14 years old who have achieved menarche and are using contraception (off-label),Treatment of premenstrual dysphoric disorder (PMDD) in women who desire oral contraception (off-label)
Prevention of pregnancy
One capsule orally once daily for 24 weeks.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinyl estradiol: CYP3A4, sulfation, glucuronidation. Drospirenone: CYP3A4, reduction, sulfation, glucuronidation.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
>=90% bound to albumin and alpha-1-acid glycoprotein.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
3.5 L/kg, indicating extensive tissue distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 87% (immediate-release); TAYTULLA formulation: 79% relative to immediate-release.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment (Cr Cl <30 m L/min); use with caution.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in patients with Child-Pugh Class B or C hepatic impairment. Use with caution in Child-Pugh Class A.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not approved for use in pediatric patients.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects; use with caution due to potential for decreased hepatic, renal, or cardiac function.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders (DVT, PE, stroke, MI), hypertension, gallbladder disease, hepatic neoplasia, hyperkalemia (especially in patients with renal/hepatic impairment or on potassium-sparing drugs), depression, impaired glucose tolerance, weight gain, fluid retention, irritability, mood changes.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast cancer, endometrial carcinoma or other estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenoma or carcinoma, known or suspected pregnancy, hypersensitivity to any component, uncontrolled hypertension, diabetes with vascular involvement, headaches with focal neurological symptoms, major surgery with prolonged immobilization, heavy smoking and age >35 years.
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No specific food interactions are known. Grapefruit juice may theoretically increase estrogen levels due to CYP3A4 inhibition, but clinical significance is unclear. Avoid excessive alcohol consumption as it may impair liver function and increase VTE risk.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
TAYTULLA (drospirenone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from inadvertent use, but postmarketing studies show a small increased risk of non-cardiac malformations. Second and third trimesters: Associated with fetal harm including cardiovascular and skeletal malformations, and feminization of male fetuses due to estrogenic effects.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Drospirenone and ethinyl estradiol are excreted in human milk in small amounts (M/P ratio not established). Use during lactation is not recommended as it may reduce milk production and composition. Alternative contraception should be considered.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
TAYTULLA is contraindicated in pregnancy; no dose adjustments are applicable as use should be discontinued immediately upon pregnancy detection. No pharmacokinetic studies in pregnancy are available.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
TAYTULLA is a combined hormonal contraceptive containing estetrol (E4) and drospirenone. It is the first contraceptive to use estetrol, a native estrogen with selective tissue activity. Its unique pharmacokinetics allow for a 24/4 regimen with a 4-day hormone-free interval. The progestin drospirenone has antimineralocorticoid activity, which can help reduce water retention and may be beneficial in patients with acne or premenstrual dysphoric disorder. Due to the risk of hyperkalemia, monitor serum potassium in patients on concomitant medications that increase potassium levels, such as ACE inhibitors, ARBs, NSAIDs, or potassium-sparing diuretics. The risk of venous thromboembolism (VTE) is present, and patients should be counseled on symptoms. TAYTULLA is contraindicated in patients with a BMI ≥ 35 kg/m² due to increased VTE risk.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one tablet daily at the same time, preferably after the evening meal. The pill pack contains 24 active tablets (white) followed by 4 placebo tablets (yellow).,If you miss a white tablet, take it as soon as you remember, even if it means taking two tablets in one day. If you miss a white tablet for more than one day, use backup contraception for the next 7 days.,This medication does not protect against HIV or other sexually transmitted infections. Use condoms for STI protection.,Common side effects include headache, nausea, breast tenderness, and mood changes. Contact your healthcare provider if you experience severe abdominal pain, chest pain, shortness of breath, or leg pain/swelling, which may indicate a blood clot.,Smoking increases the risk of serious cardiovascular side effects. Women over 35 who smoke should not use this medication.,Inform your healthcare provider of all medications you take, especially those that affect potassium levels (e.g., certain blood pressure medications, NSAIDs, potassium supplements).
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAYTULLA vs ALYACEN 1/35, answered by our medical review team.
TAYTULLA is a Oral Contraceptive that works by Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAYTULLA and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAYTULLA is: One capsule orally once daily for 24 weeks.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TAYTULLA and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TAYTULLA is classified as Category C. TAYTULLA (drospirenone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from inadvertent use, but postmarketing studies. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.